These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28607741)

  • 1. Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory.
    Bacci ED; Wyrwich KW; Phillips GA; Vollmer T; Guo S
    Mult Scler J Exp Transl Clin; 2016; 2():2055217316673235. PubMed ID: 28607741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rasch analysis of the Multiple Sclerosis Impact Scale MSIS-29.
    Ramp M; Khan F; Misajon RA; Pallant JF
    Health Qual Life Outcomes; 2009 Jun; 7():58. PubMed ID: 19545445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the impact of multiple sclerosis: Enhancing the measurement performance of the Multiple Sclerosis Impact Scale (MSIS-29) using Rasch Measurement Theory (RMT).
    Cleanthous S; Cano S; Kinter E; Marquis P; Petrillo J; You X; Wakeford C; Sabatella G
    Mult Scler J Exp Transl Clin; 2017; 3(3):2055217317725917. PubMed ID: 29104758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the Multiple Sclerosis Impact Scale-29 (MSIS-29) have the range to capture the experience of fully ambulatory multiple sclerosis patients? Learnings from the ASCLEPIOS studies.
    Regnault A; Loubert A; Brennan R; Meunier J; Naujoks C; Cano S; Adlard N
    Mult Scler J Exp Transl Clin; 2023; 9(3):20552173231201422. PubMed ID: 37780483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving the evaluation of therapeutic interventions in multiple sclerosis: development of a patient-based measure of outcome.
    Hobart JC; Riazi A; Lamping DL; Fitzpatrick R; Thompson AJ
    Health Technol Assess; 2004 Mar; 8(9):iii, 1-48. PubMed ID: 14982653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods.
    Hobart J; Cano S
    Health Technol Assess; 2009 Feb; 13(12):iii, ix-x, 1-177. PubMed ID: 19216837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychometric properties of the Croatian version of the depression, anxiety, and stress scale-21 and multiple sclerosis impact scale-29 in multiple sclerosis patients.
    Rogić Vidaković M; Šimić N; Poljičanin A; Nikolić Ivanišević M; Ana J; Đogaš Z
    Mult Scler Relat Disord; 2021 May; 50():102850. PubMed ID: 33636617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure.
    Hobart J; Lamping D; Fitzpatrick R; Riazi A; Thompson A
    Brain; 2001 May; 124(Pt 5):962-73. PubMed ID: 11335698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
    Acaster S; Swinburn P; Wang C; Stemper B; Beckmann K; Knappertz V; Pohl C; Sandbrink R; Gondek K; Edan G; Kappos L; Freedman M; Hartung HP; Arnason B; Comi G; Filippi M; Jeffery D; O'Connor P; Cook S; Lloyd AJ
    Mult Scler; 2011 Dec; 17(12):1504-13. PubMed ID: 21757536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Quality-Adjusted Life-Year Measure for Multiple Sclerosis: Developing a Patient-Reported Health State Classification System for a Multiple Sclerosis-Specific Preference-Based Measure.
    Goodwin E; Green C
    Value Health; 2015 Dec; 18(8):1016-24. PubMed ID: 26686786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity and reliability of the Finnish version of the Multiple Sclerosis Impact Scale-29.
    Rosti-Otajärvi E; Hämäläinen P; Wiksten A; Hakkarainen T; Ruutiainen J
    Brain Behav; 2017 Jul; 7(7):e00725. PubMed ID: 28729932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spanish validation of a specific measure to assess work-related problems in people with multiple sclerosis: The Multiple Sclerosis Work Difficulties Questionnaire (MSWDQ-23).
    Martínez-Ginés ML; García-Domínguez JM; Forero L; Canal N; Rebollo P; Prefasi D; Honan CA; Maurino J
    Mult Scler Relat Disord; 2018 May; 22():115-119. PubMed ID: 29656271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Sclerosis Impact Scale (MSIS-29): reliability and validity in hospital based samples.
    Riazi A; Hobart JC; Lamping DL; Fitzpatrick R; Thompson AJ
    J Neurol Neurosurg Psychiatry; 2002 Dec; 73(6):701-4. PubMed ID: 12438473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
    Phillips GA; Wyrwich KW; Guo S; Medori R; Altincatal A; Wagner L; Elkins J
    Mult Scler; 2014 Nov; 20(13):1753-60. PubMed ID: 24740371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Observational Registry of Repository Corticotropin Injection (Acthar® Gel) for the Treatment of Multiple Sclerosis Relapse.
    Kaplan J; Miller T; Baker M; Due B; Zhao E
    Front Neurol; 2020; 11():598496. PubMed ID: 33414758
    [No Abstract]   [Full Text] [Related]  

  • 16. Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    Gasperini C; Hupperts R; Lycke J; Short C; McNeill M; Zhong J; Mehta LR
    J Neurol Sci; 2016 Nov; 370():123-131. PubMed ID: 27772740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S; Vickery J; Hobart J; Wright D; Green C; Shearer J; Nunn A; Cano MG; MacManus D; Miller D; Mallik S; Zajicek J
    Health Technol Assess; 2015 Feb; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multiple sclerosis impact scale (MSIS-29) is a reliable and sensitive measure.
    McGuigan C; Hutchinson M
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):266-9. PubMed ID: 14742602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychometric evaluation of the multiple sclerosis impact scale (MSIS-29) for proxy use.
    van der Linden FA; Kragt JJ; Klein M; van der Ploeg HM; Polman CH; Uitdehaag BM
    J Neurol Neurosurg Psychiatry; 2005 Dec; 76(12):1677-81. PubMed ID: 16291893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can the ABILHAND handle manual ability in MS?
    Barrett LE; Cano SJ; Zajicek JP; Hobart JC
    Mult Scler; 2013 May; 19(6):806-15. PubMed ID: 23095289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.